SR One
Venture capital
Portfolio collected from the firm’s website, last checked Jul 26, 2026.Raises and exits come from each company’s own SEC and company records.
10Deep-tech portfolio4 active
6Portfolio exitsAcquired or listed
2Raises, 12 monthsLatest: Veradermics
19Co-investorsShare a portfolio company
Portfolio · 10 companies
| Company | Sector | Status | Latest raise | Raised |
|---|---|---|---|---|
| Addition Therapeutics | Biotech | Active | Dec 22, 2025 | $28.0M |
| Imvax | Biotech | Active | Jul 30, 2020 | $151.8M |
| Draig Therapeutics | Biotech | Active | — | — |
| F2G | Biotech | Active | — | — |
| Veradermics | Biotech | Public | May 15, 2026 | $269.3M |
| Zenas BioPharma | Biotech | Public | May 14, 2024 | $384.0M |
| Elevation Oncology | Biotech | Acquired | Nov 18, 2020 | $70.5M |
| Mersana Therapeutics | Biotech | Acquired | Jun 24, 2016 | $69.2M |
| Acelyrin | Biotech | Acquired | — | — |
| Myovant Sciences | Biotech | Acquired | — | — |
Peer ranks
Portfolio size#48
Portfolio exits#31
Raises, 12 months#12
Co-investors#113
Co-investors
- Sanofi VenturesVenture capital3 shared
- Access BiotechnologyVenture capital2 shared
- Atlas VentureVenture capital2 shared
- Canaan PartnersVenture capital2 shared
- LifeSci Venture PartnersVenture capital2 shared
- Longitude CapitalVenture capital2 shared
- SeagenVenture capital2 shared
- SV Health InvestorsVenture capital2 shared
- Versant VenturesVenture capital2 shared
- AbingworthVenture capital1 shared
Sectors
- Biotech10
Portfolios are collected from investors’ own websites and matched to tracked deep-tech companies by name; duplicate listings of the same firm are merged. Exits and raises come from each company’s own record: Form D through the latest filing.